Health
Excel
Skin Disorders Dataset – Dermatological Conditions Database
Skin Disorders Dataset
The Skin Disorders Dataset is a structured medical database containing a comprehensive list of conditions affecting the skin, hair, and nails.
Skin disorders are among the most common health conditions worldwide, ranging from mild conditions like acne and eczema to more serious diseases such as psoriasis and skin cancer. This dataset provides organised information to support medical research, healthcare analytics, and application development.
Each record includes key clinical details such as condition descriptions, affected skin areas, common symptoms, severity levels, and treatment approaches.
The dataset has been cleaned and structured for easy integration into spreadsheets, databases, and analytical tools.
It is ideal for dermatology research, healthcare developers, educators, and data scientists working with skin health data.
Dataset Contents
The dataset includes fields such as:
- Condition Name
- Description
- Affected Area (Skin, Hair, Nails)
- Common Symptoms
- Severity Level
- Disease Category
- Risk Factors
- Treatment / Management
Example Conditions Included
- Acne
- Eczema (Atopic Dermatitis)
- Psoriasis
- Rosacea
- Skin Cancer
- Melanoma
- Vitiligo
- Fungal Skin Infections
- Dermatitis
- Hives (Urticaria)
...and many more dermatological conditions.
Data Preview
12 columns
25 rows shown
| No. | Disease Name | Category | Primary Cause / Etiology | Prevalence | Age of Onset | Key Symptoms | Affected Organ(s) | Diagnostic Method | Treatment Approach | Prognosis | ICD-10 Code | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ▸ Inflammatory & Eczematous Disorders | |||||||||||
| 2 | 1 | Asteatotic Eczema (Eczema Craquelé) | Inflammatory & Eczematous Disorders | Severe xerosis (dry skin) as fundamental cause; age-related decline in natural moisturizing factors; decreased sebum production; impaired lipid synthesis in epidermis; environmental factors (low humidity, cold weather, excessive bathing, harsh soaps); diuretics causing fluid depletion; hypothyroidism association; zinc deficiency in some cases; genetic predisposition to dry skin; winter season peak | Common in elderly population (>60 years); affects up to 75% of elderly in winter months; male predominance in some studies; prevalence increases with advancing age; more common in institutionalized elderly; temperate climate areas have higher incidence; accounts for 10-15% of eczema cases in elderly | Predominantly affects elderly adults over 60 years; can occur in younger adults with predisposing factors; onset typically in winter months (October-March); chronic course with seasonal exacerbations; may first appear after hospitalization or illness; acute onset possible with severe dehydration or diuretic use | Dry, cracked skin with fine fissures creating 'crazy-paving' or 'crackled porcelain' pattern; pruritus can be intense and distressing; erythematous patches underlying fissures; polygonal scaling; predominantly affects lower legs (anterior shins 80%); may extend to thighs, trunk, arms; inflammation and oozing with severe scratching; secondary infection possible; sleep disruption from pruritus; distribution symmetric | Lower extremities (especially anterior shins); trunk; arms in extensive cases | Clinical diagnosis based on characteristic appearance and age; skin biopsy shows parakeratosis, slight spongiosis, dilated blood vessels (rarely needed); thyroid function tests to exclude hypothyroidism; serum zinc levels if deficiency suspected; rule out contact dermatitis, ichthyosis vulgaris; no specific laboratory findings | Aggressive emollient therapy (urea 10-20% cream, lactic acid 12% lotion 2-3 times daily); petroleum jelly occlusion at night; topical corticosteroids for inflammation (hydrocortisone 2.5%, triamcinolone 0.1%); oral antihistamines for pruritus (hydroxyzine 25mg HS); limit bathing frequency (every 2-3 days); warm not hot water; mild cleansers (Cetaphil, CeraVe); humidifier use; address underlying causes (thyroid replacement, zinc supplementation); avoid wool clothing | Excellent prognosis with proper skin care; 90% improvement with consistent emollient use; recurrence common each winter season requiring maintenance therapy; preventive measures highly effective; rapid improvement once dry skin addressed; chronic relapsing pattern without treatment; quality of life significantly improved with treatment; self-limiting condition if predisposing factors controlled | L85.3 |
| 3 | 2 | Atopic Dermatitis (Eczema) | Inflammatory & Eczematous Disorders | Genetic barrier dysfunction (filaggrin gene mutations in 20-30% of cases); immune dysregulation with Th2 cell dominance; elevated IgE levels; impaired ceramide synthesis; environmental triggers (allergens, irritants, stress); microbiome alterations with Staphylococcus aureus colonization (90% of lesional skin); epidermal water loss 2-3 times normal | Global prevalence 15-30% in children, 2-10% in adults (ISAAC study); affects ~230 million people worldwide; highest in industrialized nations; prevalence doubled in past 30 years; 60% onset before age 1 year, 90% before age 5; 30-40% have family history | Most common onset infancy (2-6 months); 60% present before age 1 year; 85% before age 5; can persist into adulthood in 10-30%; adult-onset form in 5-10% cases; chronic relapsing course with remission periods | Intense pruritus (hallmark symptom); erythematous patches and plaques; xerosis (dry skin); lichenification from chronic scratching; vesiculation in acute phase; oozing and crusting; distribution varies by age (face/extensor surfaces in infants, flexural areas in children/adults); excoriations; sleep disturbance in 60%; secondary bacterial infections common | Skin (epidermis and dermis); may involve conjunctiva; respiratory tract in atopic march | Clinical diagnosis using Hanifin-Rajka criteria (3+ major, 3+ minor criteria); elevated serum IgE in 80%; peripheral eosinophilia; skin prick testing for allergen identification; SCORAD index for severity assessment (score 0-103); transepidermal water loss measurement; skin biopsy shows spongiosis (rarely needed) | Emollients 2-4 times daily (ceramide-containing preferred); topical corticosteroids first-line (hydrocortisone 1-2.5% for mild, triamcinolone 0.1% moderate, clobetasol 0.05% severe); topical calcineurin inhibitors (tacrolimus 0.03-0.1%, pimecrolimus 1%); systemic therapy for severe cases (dupilumab 300mg Q2weeks, cyclosporine 3-5mg/kg/day, methotrexate 7.5-25mg weekly); phototherapy (narrowband UVB); antihistamines for pruritus; bleach baths (0.005%) twice weekly; antibiotics for secondary infection | Chronic relapsing condition with variable severity; 60-70% of childhood cases achieve remission by adolescence; 30% continue into adulthood; quality of life significantly impaired during flares; increased risk of asthma (30%), allergic rhinitis (35%), food allergies (30%); good prognosis with comprehensive management; less than 1% progress to erythroderma | L20.9 |
| 4 | 3 | Autosensitization Dermatitis (Id Reaction) | Inflammatory & Eczematous Disorders | Autoeczematization or 'id reaction' as systemic response to localized inflammatory focus; exact mechanism unclear; possible hematogenous spread of allergens, bacterial antigens, or cytokines from primary site; immune complex deposition theory; most commonly triggered by stasis dermatitis (40%), fungal infections (30%), contact dermatitis (20%); circulating antigens or altered T-cell response; cross-reactive immune response; primary site acts as sensitizing focus | Uncommon condition; exact prevalence unknown; occurs in <5% of patients with primary inflammatory dermatoses; more common in adults with chronic venous insufficiency; male and female equally affected; may occur at any age; reported in association with various primary dermatoses including tinea infections, nummular eczema, stasis dermatitis | Develops days to weeks after onset or flare of primary dermatosis; can occur at any age; often follows intensification of primary lesion; acute onset of secondary eruption; primary site precedes id reaction by days to weeks; may recur with subsequent flares of primary condition | Symmetric, generalized papulovesicular eruption distant from primary site; intense pruritus; small vesicles and papules on trunk, extremities; secondary sites morphologically different from primary lesion (vesicular vs. primary dermatitis); primary inflammatory focus usually evident (stasis dermatitis, tinea pedis, infected eczema); resolution follows treatment of primary site; distribution symmetric and generalized; no direct contact with primary lesion | Skin distant from primary inflammatory site; trunk and extremities predominantly; generalized distribution | Clinical diagnosis based on temporal relationship to primary dermatosis and distant location; KOH preparation of primary site if fungal suspected; bacterial culture if infection present; skin biopsy of id reaction shows spongiotic dermatitis (nonspecific); identification and confirmation of primary dermatosis essential; patch testing if contact dermatitis primary cause; rule out primary generalized eruption or drug reaction | Treat primary inflammatory focus (cornerstone of management): antifungals for tinea (terbinafine 250mg daily 2-4 weeks), antibiotics for infected eczema (cephalexin 500mg QID), compression and topical corticosteroids for stasis dermatitis; secondary eruption treated with mid-potency topical corticosteroids (triamcinolone 0.1% twice daily); oral antihistamines for pruritus; oral corticosteroids for severe id reaction (prednisone 40-60mg tapering over 2-3 weeks); emollients; cool compresses; id reaction resolves as primary site improves | Excellent prognosis; id reaction resolves within 1-3 weeks once primary focus treated; 90-95% clearance with appropriate management of primary dermatosis; recurrence possible with recurrence of primary condition; no long-term sequelae; rapid improvement once primary site controlled; self-limiting once trigger eliminated; favorable outcomes with proper diagnosis and treatment of primary site | L30.2 |
| 5 | 4 | Contact Dermatitis (Allergic) | Inflammatory & Eczematous Disorders | Type IV delayed hypersensitivity reaction; T-cell mediated immune response to specific allergens; sensitization phase requires 5-21 days; elicitation phase 24-72 hours after re-exposure; common allergens include nickel (14% of population), fragrances (2-4%), preservatives (methylisothiazolinone), rubber chemicals, para-phenylenediamine in hair dyes; cross-reactivity patterns with structurally similar compounds | Affects 15-20% of general population at some point; accounts for 20-25% of occupational skin diseases; nickel allergy affects 8-19% of women, 1-3% of men; occupational incidence 0.5-1.9 per 1000 person-years; healthcare workers, hairdressers, construction workers at highest risk | Can develop at any age; occupational forms typically in young adults (20-40 years); nickel allergy often manifests in adolescence with ear piercing; cumulative exposure over months to years before sensitization; can develop after years of safe use | Pruritic erythematous papules and vesicles; weeping and crusting in acute phase; well-demarcated patches corresponding to contact area; geometric or linear patterns common; lichenification with chronic exposure; edema and erosions in severe cases; distribution provides diagnostic clues (earlobes for nickel, wrists for fragrances); systemic contact dermatitis possible with oral exposure | Skin (epidermis primarily); regional lymph nodes may be involved | Patch testing (gold standard, sensitivity 70-80%); TRUE Test or Thin-layer Rapid Use Epicutaneous Test; reading at 48 and 96 hours; positive reactions graded 1+ to 3+; repeat open application test (ROAT) for confirmation; detailed exposure history critical; skin biopsy shows spongiosis with eosinophils (if needed) | Allergen identification and avoidance (cornerstone of management); topical corticosteroids (betamethasone valerate 0.1%, mometasone 0.1% once daily); systemic corticosteroids for severe cases (prednisone 0.5-1mg/kg tapering over 2-3 weeks); oral antihistamines (hydroxyzine 25-50mg, cetirizine 10mg daily); emollients and barrier repair; occupational modifications or personal protective equipment; desensitization rarely used | Excellent prognosis with allergen avoidance; 60-80% clear completely when exposure eliminated; chronic cases develop with continued exposure; occupational forms may require career change in 10-15% cases; recurrence immediate upon re-exposure; quality of life impairment moderate to severe during active disease | L23.9 |
| 6 | 5 | Contact Dermatitis (Irritant) | Inflammatory & Eczematous Disorders | Direct cytotoxic damage to keratinocytes from chemical, physical, or biological irritants; non-immunologic mechanism; disruption of stratum corneum barrier; lipid extraction by solvents; denaturation of keratin proteins; common irritants include soaps, detergents, acids, alkalis, solvents, water (chronic wet work); cumulative insult dermatitis most common form; accounts for 80% of contact dermatitis cases | Most common occupational skin disease (70-80% of work-related dermatitis); affects 20-35% of healthcare workers; 5-10% of general population affected; incidence 0.7-1.4 per 1000 person-years in occupational settings; hand dermatitis affects 5-10% of general population annually | Any age; most common in working adults (25-50 years); acute form can occur after single exposure; chronic cumulative form develops after weeks to months of repeated exposure; infants at risk for diaper dermatitis; onset directly related to intensity and duration of exposure | Burning, stinging, pain more prominent than itching; erythema and scaling; fissuring and cracking of hands/fingers; hyperkeratosis in chronic cases; vesiculation less common than allergic form; diffuse involvement without sharp margins; affects dorsal hands, finger webs, palms; erosions and ulceration with strong irritants; symptoms improve on weekends/holidays (occupational clue) | Skin (epidermis and upper dermis); hands involved in 80% of cases | Clinical diagnosis based on exposure history; patch testing negative (distinguishes from allergic); rapid onset after known irritant exposure; lack of sensitization phase; improvement away from exposure; skin biopsy shows necrotic keratinocytes, neutrophilic infiltrate (rarely needed); transepidermal water loss elevated | Irritant identification and avoidance; frequent emollient use (4-6 times daily); barrier creams before exposure; topical corticosteroids (triamcinolone 0.1%, fluocinonide 0.05% twice daily); hand protection with cotton-lined gloves; wet work reduction below 2 hours/day; job modification if occupational; tacrolimus 0.1% for hand dermatitis; oral corticosteroids rarely needed for severe acute cases | Good prognosis with exposure reduction and barrier restoration; 50-70% improve with proper management; chronic cases may persist despite treatment; occupational forms lead to job change in 20-30% severe cases; recurrence common with continued exposure; barrier function recovers slowly over weeks to months | L24.9 |
| 7 | 6 | Diaper Dermatitis | Inflammatory & Eczematous Disorders | Multifactorial: prolonged contact with urine and feces causing skin maceration; ammonia from bacterial urease breaking down urea; increased skin pH (normal 5.5 to >7); enhanced penetration of irritants and enzymes (proteases, lipases); friction from diaper; occlusive environment; Candida albicans superinfection in 50-75% of cases lasting >3 days; breast-fed infants have lower incidence; antibiotic use increases risk | Affects 7-35% of infants with peak 9-12 months of age; most common dermatosis in infancy; prevalence varies by diaper changing frequency and type; occurs in 90% of infants at some point; increased incidence with diarrhea, antibiotics, teething; developed countries: 25% point prevalence; cloth diapers may have higher rates than superabsorbent disposables | Onset typically after 3 weeks of age; peak incidence 9-12 months; resolves with toilet training (usually by age 2-3 years); individual episodes last 2-4 days on average; can occur at any age using diapers (elderly incontinence); recurrent episodes common throughout diaper-wearing period | Erythema in diaper area (buttocks, thighs, genitals); sparing of skin folds (differentiates from Candida); shiny glazed appearance; papules and shallow erosions; pain and irritability with diaper change; perianal involvement; satellite lesions suggest Candida superinfection; fissuring in severe cases; beefy red plaques; restlessness and crying; secondary bacterial infection in severe cases | Perineal area; buttocks; lower abdomen; medial thighs covered by diaper | Clinical diagnosis based on distribution and appearance; KOH preparation for satellite lesions (Candida); bacterial culture if impetigo suspected; skin biopsy rarely needed; zinc levels if recalcitrant (acrodermatitis enteropathica); consider immunodeficiency if severe or treatment-resistant | Frequent diaper changes (every 2-3 hours or immediately after soiling); barrier paste with zinc oxide >40% or petrolatum at each change; gentle cleansing with warm water; air exposure when possible; low-potency topical corticosteroid for severe inflammation (hydrocortisone 1% twice daily max 1-2 weeks); topical antifungals if Candida present (nystatin, clotrimazole twice daily); avoid baby wipes with fragrance/alcohol; superabsorbent disposable diapers preferred; oral nystatin if concurrent oral thrush | Excellent prognosis; 90% resolve within 2-3 days with proper care; prevention key with frequent changes and barrier use; recurrence common but manageable; no long-term sequelae; severe cases may lead to erosions requiring weeks to heal; Candida superinfection extends course to 1-2 weeks; self-limiting with toilet training; favorable outcomes with caregiver education | L22 |
| 8 | 7 | Drug Eruption (Morbilliform) | Inflammatory & Eczematous Disorders | Type IV T-cell mediated delayed hypersensitivity reaction; drug acting as hapten binding to protein carriers; most common culprits: antibiotics (penicillins, cephalosporins, sulfonamides), anticonvulsants (phenytoin, carbamazepine), allopurinol, NSAIDs; genetic predisposition with HLA associations; onset typically 4-14 days after drug initiation; risk factors include viral infections (EBV, HIV), immune status; accounts for 90-95% of drug eruptions | Occurs in 2-3% of hospitalized patients receiving medications; antibiotics cause 40-50% of cases; most common cutaneous adverse drug reaction; beta-lactam antibiotics: 1-10% incidence; allopurinol: 2% develop rash; higher incidence with aminopenicillins + EBV (55-100%); all ages affected; no strong gender predilection | Typically 4-14 days after starting culprit medication; can occur within 1-3 days on re-exposure; viral prodrome may precede in some cases; onset after first dose rare; may start up to several days after discontinuation; median onset 7-9 days; acute onset over 1-2 days once started | Symmetric erythematous macules and papules; 'morbilliform' (measles-like) or 'exanthematous' pattern; starts on trunk and spreads to extremities; pruritus variable (mild to severe); bright red to dusky red color; may become confluent; desquamation in resolution phase after 1-2 weeks; fever low-grade or absent (if present with systemic symptoms, consider DRESS); palms and soles involved in 50%; mucous membranes typically spared | Skin (trunk and extremities); face may be involved; mucous membranes usually spared | Clinical diagnosis based on temporal relationship to medication and morphology; skin biopsy shows perivascular lymphocytic infiltrate, spongiosis, eosinophils (not specific); complete blood count may show eosinophilia (<1000/μL); liver and kidney function to exclude DRESS or other severe reactions; drug causality assessment using Naranjo algorithm; lymphocyte transformation test research tool (not routine); patch testing for confirmation after resolution | Discontinue suspected offending drug; most resolve within 1-2 weeks after discontinuation; topical corticosteroids for pruritus (triamcinolone 0.1%, hydrocortisone 2.5%); oral antihistamines (cetirizine 10mg, loratadine 10mg daily); emollients; oral corticosteroids rarely needed unless severe (prednisone 0.5mg/kg for 5-7 days); symptomatic treatment; cool compresses; monitor for progression to severe cutaneous adverse reactions (Stevens-Johnson syndrome, DRESS) | Excellent prognosis; self-limiting condition; 90-95% resolve completely within 1-2 weeks of drug discontinuation; rare progression to severe reactions (<1%); post-inflammatory hyperpigmentation may persist for weeks to months; no long-term sequelae; recurrence upon re-exposure (contraindicated); alternative medications usually available; favorable outcomes with supportive care | L27.0 |
| 9 | 8 | Dyshidrotic Eczema (Pompholyx) | Inflammatory & Eczematous Disorders | Unknown exact etiology; possibly related to sweat gland dysfunction (name pompholyx from Greek 'bubble'); atopic diathesis in 50% cases; contact allergy triggers in 30-40% (nickel, chromium, balsam of Peru); emotional stress exacerbation; seasonal pattern with spring/summer flares; possible hyperhidrosis association; systemic contact dermatitis from dietary nickel in sensitized individuals; smoking increases risk | Accounts for 5-20% of hand eczema cases; annual incidence 1-2 per 1000 population; affects both sexes equally or slight female predominance; more common in atopic individuals (relative risk 2-3); peak prevalence in young adults aged 20-40 years; seasonal peaks in spring and summer | Most common onset in young adults (20-40 years); chronic relapsing pattern over years to decades; episodes last 3-4 weeks on average; frequency varies from monthly flares to annual occurrences; some patients have single episode; childhood onset less common but possible | Sudden onset of intensely pruritic vesicles on palms, soles, lateral fingers; 1-2mm deep-seated vesicles ('tapioca-like'); symmetrical distribution; vesicles may coalesce into bullae; desquamation follows vesicle phase after 2-3 weeks; burning and pain in severe cases; fissuring with scaling phase; feet involved in 20-30%; hand function impairment; secondary bacterial infection in 10-15% | Palms; lateral aspects of fingers; soles of feet; sides of hands | Clinical diagnosis based on characteristic vesicles and distribution; patch testing for contact allergens (30-40% positive); KOH preparation to exclude tinea; bacterial culture if secondary infection suspected; skin biopsy shows spongiotic dermatitis with intraepidermal vesicles (rarely performed); dietary nickel challenge in selected cases | High-potency topical corticosteroids (clobetasol 0.05% ointment twice daily); topical calcineurin inhibitors (tacrolimus 0.1%); systemic corticosteroids for severe episodes (prednisone 40-60mg tapering 2-3 weeks); oral antihistamines; aluminum chloride hexahydrate 20% for hyperhidrosis; phototherapy (PUVA or narrowband UVB); systemic immunosuppressants for refractory cases (methotrexate 7.5-15mg weekly, azathioprine 1-3mg/kg/day); botulinum toxin injection for severe cases; low-nickel diet if sensitivity confirmed | Chronic relapsing condition with variable severity; 80% have recurrent episodes over years; some patients achieve spontaneous remission; quality of life significantly impaired during flares; 50-70% respond well to topical corticosteroids; functional disability in severe cases; no increased malignancy risk; favorable prognosis with trigger avoidance and maintenance therapy | L30.1 |
| 10 | 9 | Erythroderma (Exfoliative Dermatitis) | Inflammatory & Eczematous Disorders | Generalized inflammatory response involving >90% body surface area; multiple etiologies: psoriasis (20-25%), eczema/atopic dermatitis (15-20%), drug reactions (15-20%), cutaneous T-cell lymphoma/Sézary syndrome (10-15%), idiopathic (25%); pathophysiology includes massive cytokine release, increased epidermal turnover (3-4 fold), capillary dilation, thermoregulation impairment; protein loss through scaling (10-20g/day); high-output cardiac state; increased metabolic rate 50% | Rare condition with incidence 1-2 per 100,000 population annually; male predominance 2-4:1; average age 40-60 years but any age affected; accounts for 1-2% of dermatology admissions; associated with underlying dermatoses in 60-75%; mortality rate 10-20% in acute cases; higher mortality in elderly and immunocompromised | Can occur at any age; underlying dermatoses typically precede erythroderma by years; drug-induced forms acute onset over days to weeks; chronic forms develop over weeks to months; peak incidence in middle-aged to elderly adults; may be presenting sign of cutaneous lymphoma; neonatal forms rare (Omenn syndrome, Netherton syndrome) | Diffuse erythema involving >90% body surface area; generalized scaling and exfoliation; pruritus intense and constant; skin tightness; edema of hands and feet; palmoplantar keratoderma; nail changes (thickening, ridging, onycholysis); hair loss (telogen effluvium); systemic symptoms: fever, chills, malaise, lymphadenopathy (50-80%); hypothermia in severe cases; tachycardia; high-output cardiac failure possible | Entire skin surface (>90% involvement by definition); lymph nodes; systemic effects on cardiovascular, thermoregulatory systems | Clinical diagnosis based on extent of involvement; skin biopsies from multiple sites (may show underlying cause); complete blood count (anemia, eosinophilia, lymphocytosis); comprehensive metabolic panel (hypoalbuminemia 2-3g/dL, electrolyte abnormalities); liver function tests; flow cytometry if Sézary syndrome suspected (CD4/CD8 ratio, T-cell clonality); peripheral blood smear for Sézary cells; lactate dehydrogenase elevated; total protein and albumin decreased; thorough medication review | Hospitalization for acute cases (hemodynamic monitoring, fluid/electrolyte management); treat underlying cause (psoriasis, eczema, discontinue drug); topical emollients extensively; mid-potency topical corticosteroids (triamcinolone 0.1%); systemic corticosteroids (prednisone 0.5-1mg/kg/day tapering); cyclosporine 3-5mg/kg/day; methotrexate 10-25mg weekly; biologic agents (infliximab, adalimumab, ustekinumab) for psoriatic erythroderma; temperature regulation support; antihistamines; nutritional support with high-protein diet; phototherapy after acute phase; treat secondary infections | Variable prognosis depending on etiology; drug-induced forms: excellent prognosis, resolve in 2-6 weeks; psoriasis/eczema: chronic relapsing, good prognosis with treatment; lymphoma-associated: poor prognosis, median survival 4-5 years; idiopathic: chronic course, 20-30% eventually diagnosed with lymphoma; overall mortality 10-20% in acute phase from sepsis, cardiac failure, pneumonia; favorable outcomes with early treatment and underlying cause identification | L26 |
| 11 | 10 | Graft-versus-Host Disease (Cutaneous) | Inflammatory & Eczematous Disorders | Donor T-lymphocytes recognize recipient tissues as foreign after allogeneic hematopoietic stem cell transplant (HSCT); acute GVHD occurs within first 100 days post-transplant; chronic GVHD after 100 days or later; cytokine storm (IL-1, IL-6, TNF-α) during conditioning regimen; donor T-cell activation and expansion; target organ damage to skin, liver, GI tract; risk factors include HLA mismatch, unrelated donor, female to male transplant, older recipient age, intensity of conditioning regimen | Occurs in 30-50% of allogeneic HSCT recipients (acute form); chronic GVHD in 30-70% of HSCT survivors; increasing incidence with transplant for non-malignant conditions; reduced-intensity conditioning has not significantly decreased incidence; skin involved in 80% of acute GVHD, 70% of chronic GVHD; accounts for significant morbidity and mortality post-transplant; leading cause of non-relapse mortality | Acute GVHD: median onset 14-21 days post-transplant (range 7-100 days); chronic GVHD: onset >100 days post-transplant (median 4-12 months); can develop years after transplant; de novo chronic GVHD in 30%, progressive from acute in 40%, quiescent onset in 30%; higher risk with matched unrelated donors compared to siblings | Acute GVHD: maculopapular erythematous rash starting on palms, soles, ears; spreads to trunk; pruritus variable; may progress to confluent erythema, bullae in severe cases (grade 4: toxic epidermal necrolysis-like); graded I-IV based on body surface area involved. Chronic GVHD: lichenoid papules and plaques; poikiloderma; sclerotic skin (scleroderma-like); nail dystrophy; hair loss; mucous membrane involvement; vitiligo-like changes; contractures in severe sclerotic form; significant functional impairment | Skin (acute: palms, soles, ears initially; chronic: trunk, extremities); liver; gastrointestinal tract; lungs (bronchiolitis obliterans); eyes; mucous membranes | Clinical diagnosis using NIH consensus criteria; skin biopsy (acute: vacuolar interface dermatitis, dyskeratotic keratinocytes, satellite cell necrosis; chronic: lichenoid infiltrate, dermal sclerosis); grading system for severity assessment; liver function tests (elevated bilirubin, alkaline phosphatase); stool studies if GI symptoms; pulmonary function tests for chronic GVHD; biomarkers (ST2, REG3α) investigational | Acute GVHD: topical corticosteroids for grade I (clobetasol 0.05%); systemic corticosteroids first-line for grade II-IV (methylprednisolone 2mg/kg/day); calcineurin inhibitors (tacrolimus target 5-15ng/mL, cyclosporine 200-400ng/mL); mycophenolate mofetil 1g twice daily; extracorporeal photopheresis; ruxolitinib 5-10mg twice daily for steroid-refractory. Chronic GVHD: prednisone 1mg/kg/day with taper; calcineurin inhibitors; imatinib for sclerotic form; phototherapy (UVA1, narrowband UVB); supportive care (emollients, physical therapy for sclerosis) | Acute GVHD prognosis: grade I-II 80-90% survival; grade III-IV 25-50% survival; overall response to first-line therapy 40-50%. Chronic GVHD: chronic relapsing course requiring years of immunosuppression; complete resolution in 30-40%; moderate-severe forms significantly impact quality of life; 5-year survival 50-70% with chronic GVHD; extensive sclerotic disease poorest prognosis; infection risk from immunosuppression; new targeted therapies improving outcomes | D89.813 |
| 12 | 11 | Intertrigo | Inflammatory & Eczematous Disorders | Inflammatory dermatosis of intertriginous areas caused by friction, heat, moisture; maceration from sweat and occlusion; compromised skin barrier; secondary infection common: Candida albicans (60-80%), bacteria (Staphylococcus aureus, Streptococcus, Corynebacterium), dermatophytes; obesity major risk factor (BMI >30 increases risk 3-fold); diabetes mellitus increases susceptibility; immobility; incontinence; hyperhidrosis; poor hygiene | Common condition; prevalence 7-10% in general population, up to 40% in obese individuals; affects all ages but more common in elderly; nursing home prevalence 15-20%; no gender predilection; higher incidence in summer months; institutional settings have increased prevalence; diabetic patients 2-3 times higher risk | Any age; more common in infants (neck folds), obese adults, elderly; chronic condition with acute exacerbations; seasonal variation with summer flares; onset associated with weight gain, hot weather, new-onset diabetes, immobility; can develop rapidly within days in predisposed individuals | Erythematous patches in skin folds; maceration with white, soggy appearance; burning, itching, pain; foul odor if bacterial superinfection; fissuring at base of folds; satellite papules and pustules suggest Candida; borders may be sharp or indistinct; exudate and crusting; erosions in severe cases; affected areas: submammary, axillary, inguinal, abdominal pannus, intergluteal; worsens with activity and heat | Intertriginous areas: axillae; groin; submammary; abdominal folds; intergluteal cleft; neck in infants | Clinical diagnosis based on location and appearance; Wood's lamp examination (coral-red fluorescence for Corynebacterium minutissimum erythrasma); KOH preparation for Candida or dermatophytes (pseudohyphae if Candida); bacterial culture if bacterial infection suspected; skin swab for specific pathogen identification; blood glucose to screen for diabetes; skin biopsy rarely needed but shows psoriasiform hyperplasia | Keep affected areas clean and dry (cornerstone of management); gentle drying after washing; barrier creams (zinc oxide); absorbent powders (miconazole powder if yeast); low-potency topical corticosteroids (hydrocortisone 1-2.5% twice daily) short-term; topical antifungals if Candida (clotrimazole 1%, nystatin twice daily); topical antibiotics if bacterial (mupirocin twice daily); systemic antifungals for extensive Candida (fluconazole 150mg weekly); weight loss; moisture-wicking fabrics; interlesional gauze or absorptive dressings | Good prognosis with preventive measures; chronic relapsing condition without weight loss and preventive care; recurrence rate high (50-60%) without lifestyle modifications; acute episodes respond well to treatment within 1-2 weeks; secondary infections may complicate course; quality of life impact moderate; favorable outcomes with weight reduction and meticulous skin care; rarely leads to complications if managed properly | L30.4 |
| 13 | 12 | Neurodermatitis (Lichen Simplex Chronicus) | Inflammatory & Eczematous Disorders | Itch-scratch cycle as central mechanism; initial pruritus from minor trauma, insect bite, or psychological stress; repeated scratching leads to epidermal thickening and perpetuation of itch; neurogenic inflammation with neuropeptide release (substance P); psychological factors in 50-70% (anxiety, obsessive-compulsive traits); conditioned response behavior; sensory nerve sensitization; may occur on background of atopic dermatitis (20-30% cases) | Prevalence 12% in general population; female predominance 2:1; more common in adults 30-50 years; accounts for 10-12% of dermatology visits; Asian ethnicity higher prevalence; associated with anxiety disorders in 50%, depression in 30%; increased incidence in atopic individuals | Most common onset in middle-aged adults (30-50 years); can occur at any age after childhood; chronic course lasting months to years; some cases persist throughout lifetime; stress-related flares; may start after insect bite, eczema patch, or psychosocial stress; gradual onset over weeks | Solitary or few lichenified plaques with exaggerated skin markings; intense, paroxysmal pruritus worse at rest and night; well-demarcated thick plaque(s); excoriations and crusting from scratching; hyperpigmentation or hypopigmentation; common sites: nape of neck, scalp, ankles, shins, forearms, vulva, scrotum, perianal area; automatic scratching behavior; focal pruritus and pain; significant sleep disturbance; obsessive scratching | Skin (localized areas); commonly nape of neck; ankles; genital region; scalp | Clinical diagnosis based on lichenification and scratching behavior; dermoscopy shows hyperkeratosis, prominent follicular openings; skin biopsy shows hyperkeratosis, acanthosis, vertical collagen bundles in dermis (lichen simplex chronicus histology); psychological assessment may be helpful; rule out underlying dermatoses (psoriasis, eczema, fungal infection); patch testing if contact dermatitis component suspected | Break itch-scratch cycle with occlusive dressings; super-potent topical corticosteroids (clobetasol 0.05% twice daily under occlusion); intralesional triamcinolone 5-10mg/mL every 3-4 weeks; topical calcineurin inhibitors (tacrolimus 0.1%); antihistamines especially sedating at night (hydroxyzine 50mg, doxepin 25-50mg HS); capsaicin cream 0.025% to decrease neuropeptide; cooling menthol preparations; habit reversal behavioral therapy; treat underlying anxiety/depression (SSRIs); gabapentin 300-900mg for neuropathic itch; physical barriers (covering affected area) | Good prognosis if itch-scratch cycle broken; 70-80% clear with intensive treatment over 2-3 months; high recurrence rate (50-60%) with stress or trigger exposure; chronic relapsing course common; residual pigmentation may persist for months; significant quality of life impairment; favorable outcome with behavioral modification and treatment adherence; psychological counseling improves outcomes | L28.0 |
| 14 | 13 | Nummular Dermatitis | Inflammatory & Eczematous Disorders | Multifactorial etiology; impaired skin barrier function with increased transepidermal water loss; possible relationship to bacterial colonization (Staphylococcus aureus in 50-60%); dry skin (xerosis) as major predisposing factor; winter season exacerbation; possible hypersensitivity to Staphylococcus proteins; contact sensitivity in 30-40% cases; stress and alcohol consumption as triggers | Accounts for 2-9% of all eczema cases; more common in males (2-3:1 ratio); incidence 0.5-2 per 1000 population; peaks in middle age (40-60 years) and elderly (>65 years); seasonal variation with winter predominance; geographic variation with higher rates in cold, dry climates | Bimodal age distribution: young adults (15-25 years, predominantly female) and middle-aged to elderly (50-65 years, predominantly male); chronic course with average duration 6-12 months; can persist for years; recurrences common | Coin-shaped (nummular) erythematous plaques 1-10cm diameter; intense pruritus interfering with sleep; lesions ooze and crust in acute phase; well-demarcated circular patches; scaling at periphery; vesiculation less prominent; favors extensor surfaces (dorsal hands, forearms, lower legs); trunk involvement in severe cases; scratching leads to lichenification; secondary infection common (impetiginized) | Skin (primarily extremities); lower legs most commonly affected (60-70% cases) | Clinical diagnosis based on characteristic morphology and distribution; skin biopsy shows spongiosis, acanthosis, parakeratosis (if needed); bacterial culture for secondary infection; patch testing if contact allergy suspected (positive in 30-40%); KOH to exclude fungal infection; complete blood count usually normal | High-potency topical corticosteroids (clobetasol 0.05%, betamethasone dipropionate 0.05% twice daily); wet wrap therapy for severe cases; systemic corticosteroids for extensive disease (prednisone 40-60mg tapering over 2-3 weeks); oral antibiotics for secondary infection (cephalexin 500mg QID, doxycycline 100mg BID); antihistamines for pruritus (hydroxyzine 25-50mg HS); emollients frequently; phototherapy (narrowband UVB) for refractory cases; calcineurin inhibitors for maintenance | Chronic relapsing course but eventual resolution in most cases; 50-70% clear within 6-12 months with treatment; residual post-inflammatory hyperpigmentation common; recurrence rate 30-40%; more persistent in elderly; good response to combination therapy; quality of life significantly impaired during active disease; prognosis favorable with proper management | L30.0 |
| 15 | 14 | Perioral Dermatitis | Inflammatory & Eczematous Disorders | Exact etiology unknown; topical corticosteroid use as major trigger (60-90% cases); fluorinated toothpaste possible factor; cosmetics and moisturizers; occlusive conditions; altered skin microbiome; possible role of Demodex folliculorum, Candida, or bacteria (Fusiform bacteria); hormonal factors in women; UV light exposure; recent theories suggest barrier dysfunction; immunologic factors | Predominantly affects young women aged 15-45 years (female to male ratio 9:1); prevalence 0.5-1% of general population; increasing incidence possibly related to cosmetic use; children account for 5-10% of cases; more common in fair-skinned individuals; occupational prevalence higher in flight attendants, workers exposed to occupational irritants | Peak onset in women aged 20-45 years; children can be affected (mean age 5-13 years in pediatric cases); acute to subacute onset over weeks; chronic course if untreated; often develops after prolonged topical corticosteroid use; gradual onset typically | Erythematous papules and pustules around mouth (perioral); characteristic clear zone sparing vermilion border; scaling and flaking; mild burning or itching; may extend to nasolabial folds and chin; periocular involvement in 15-20% (periorificial dermatitis); granulomatous variant rare; symptoms worsen with topical corticosteroid use then improve temporarily; dry, tight skin sensation; worsens with fluorinated toothpaste | Perioral skin (sparing vermilion border); nasolabial folds; chin; periorbital area less commonly | Clinical diagnosis based on characteristic distribution and morphology; dermoscopy shows follicular papules, scaling, erythema; skin biopsy shows perifollicular lymphohistiocytic infiltrate, follicular spongiosis (if needed); bacterial culture usually negative; differentiation from rosacea, seborrheic dermatitis, acne important; potassium hydroxide for yeast if suspected | Discontinue all topical corticosteroids (initial flare expected for 1-2 weeks); oral tetracyclines first-line (doxycycline 50-100mg twice daily 6-12 weeks, minocycline 50-100mg twice daily); topical metronidazole 0.75-1% twice daily or azelaic acid 15% twice daily; topical pimecrolimus 1% or tacrolimus 0.03%; oral erythromycin 250-500mg twice daily in children or pregnancy; avoid fluorinated toothpaste; gentle skin care only; sunscreen use; oral isotretinoin 0.3-0.5mg/kg/day for refractory cases | Excellent prognosis with treatment; 80-90% clear with oral antibiotics within 2-3 months; recurrence rate 10-20% especially with trigger re-exposure; self-limiting in some cases but may take 6-12 months; residual erythema may persist for weeks; good cosmetic outcome; challenging if corticosteroid discontinuation difficult; favorable response to oral tetracyclines in majority | L71.0 |
| 16 | 15 | Photodermatitis | Inflammatory & Eczematous Disorders | Abnormal skin reaction to ultraviolet (UV) radiation or visible light; UVA (320-400nm) and UVB (280-320nm) both implicated; phototoxic reactions from medications (tetracyclines, NSAIDs, thiazides, quinolones, amiodarone) or plants (psoralens in limes, celery); photoallergic reactions type IV hypersensitivity with 24-48 hour delay; endogenous photosensitizers (porphyrins in porphyria cutanea tarda); polymorphous light eruption most common idiopathic form (10-15% of population) | Polymorphous light eruption affects 10-15% of general population in temperate climates; female predominance 2-3:1; higher prevalence in northern latitudes; phototoxic drug reactions account for 8% of cutaneous drug reactions; hereditary forms rare (erythropoietic protoporphyria 1:75,000-200,000); all ages affected; sun-exposed populations have adapted lower rates | Polymorphous light eruption typically starts in adolescence or young adulthood (20-30 years); can develop at any age; seasonal pattern (spring and early summer when UV exposure increases); medication-induced forms at any age; chronic actinic dermatitis typically older adults >50 years; rapid onset after UV exposure (minutes to hours for phototoxic, 24-72 hours for photoallergic) | Pruritic erythematous papules and plaques on sun-exposed areas (face, neck, arms, V-chest); sharp cutoff at clothing lines; sparing of habitually exposed areas (face, hands) in polymorphous light eruption; vesicles and bullae in severe phototoxic reactions; eczematous changes in chronic cases; 'hardening' effect with repeated exposure in some forms; burning and stinging in acute phase; morphology varies (papular, vesicular, plaque forms) | Sun-exposed skin: face; V-neck; dorsal hands; extensor arms; ears; lower legs in skirt/shorts wearers | Photopatch testing (photoallergy); phototesting to determine minimal erythema dose (MED); skin biopsy shows dermal edema, perivascular lymphocytic infiltrate; porphyrin levels (urine, stool, blood) if porphyria suspected; medication review for photosensitizers; antinuclear antibodies to exclude lupus; provocation testing with controlled UV exposure; complete blood count, liver function tests | Sun avoidance during peak hours (10am-4pm); broad-spectrum sunscreen SPF 50+ (reapply every 2 hours); protective clothing (UPF 50+); discontinue photosensitizing medications if possible; topical corticosteroids (fluocinolone 0.025%, betamethasone valerate 0.1%); oral corticosteroids for severe reactions (prednisone 40-60mg tapering); antihistamines for pruritus; desensitization phototherapy (narrowband UVB 3x/week gradually increasing); hydroxychloroquine 200-400mg daily for prevention in chronic cases; oral beta-carotene, nicotinamide for prophylaxis | Variable prognosis depending on type; polymorphous light eruption improves with age in 30-40%, chronic relapsing in others; excellent prognosis with sun protection and trigger avoidance; phototoxic reactions resolve within days of medication discontinuation; photoallergic reactions may persist for months; 'hardening' phenomenon allows increased tolerance in some cases; quality of life impact moderate to severe in summer months; good control with preventive measures | L56.9 |
| 17 | 16 | Prurigo Nodularis | Inflammatory & Eczematous Disorders | Itch-scratch cycle leads to nodule formation; chronic repetitive scratching and rubbing; neurogenic inflammation with nerve fiber proliferation in lesions; possible immune dysregulation; associated conditions in 50-80%: atopic dermatitis, chronic kidney disease, liver disease, HIV, hematologic malignancies, thyroid disorders, diabetes; elevated IL-31 levels (itch cytokine); psychological factors (stress, anxiety, depression) in 40-70%; central and peripheral sensitization | Prevalence 0.5-5% in dermatology clinics; female predominance (2-3:1); more common in middle-aged and elderly adults; African American patients disproportionately affected; associated with chronic pruritus; exact epidemiology unclear due to underreporting; significant burden on quality of life; increased incidence in patients with end-stage renal disease (25-40%) | Most common onset in middle-aged adults (40-65 years); chronic course lasting months to years; associated with chronic systemic diseases; onset may follow insect bite, eczema, or emotional stress; gradual development over weeks to months; can persist for years if underlying cause not addressed | Multiple firm, hyperkeratotic nodules 0.5-3cm diameter; intense, persistent pruritus; excoriated crusted surface; hyperpigmented or hypopigmented; symmetric distribution on extensor surfaces (arms, legs); dorsal hands and feet; upper back; sparing of mid-back ('butterfly sign' where patient cannot reach); top of nodules often have erosion or crust from scratching; significant sleep disruption; automatic scratching behavior; 10-100+ nodules possible | Extensor surfaces of extremities; upper back (reachable areas); dorsal hands and feet | Clinical diagnosis based on characteristic nodules and pruritus; skin biopsy shows hyperkeratosis, acanthosis, dermal fibrosis, neural hyperplasia (helpful to confirm); complete blood count, comprehensive metabolic panel, liver function tests, thyroid function; HIV testing; chest X-ray; urinalysis; age-appropriate cancer screening; serum IgE; workup for internal disease if suggested by history; neurophysiologic studies may show nerve fiber density changes | Super-potent topical corticosteroids (clobetasol 0.05% under occlusion); intralesional triamcinolone 10-40mg/mL every 3-4 weeks; topical calcineurin inhibitors (tacrolimus 0.1%); capsaicin 0.025-0.1% cream to deplete substance P; antihistamines (hydroxyzine, doxepin); gabapentin 300-1800mg/day or pregabalin 75-300mg/day; oral naltrexone 50mg daily (opioid antagonist); thalidomide 50-200mg/day (teratogenic, requires monitoring); dupilumab 300mg Q2weeks; phototherapy (narrowband UVB); treat underlying conditions; cryotherapy; excision for solitary lesions | Chronic relapsing condition with challenging management; 50-60% partial response to treatment; complete clearance difficult; residual scarring and pigmentation common; quality of life severely impaired; breaking itch-scratch cycle critical; newer biologics (dupilumab) showing 50-60% improvement; prognosis improves with identification and treatment of underlying conditions; many patients require multimodal therapy; favorable outcomes in 30-40% with aggressive management | L28.1 |
| 18 | 17 | Seborrheic Dermatitis | Inflammatory & Eczematous Disorders | Malassezia yeast overgrowth (lipophilic species M. restricta, M. globosa); inflammatory response to Malassezia metabolites; sebaceous gland hyperactivity; genetic predisposition with familial clustering; neurologic disease association (Parkinson's in 30-80%); immunosuppression increases severity; stress and cold weather exacerbations; altered skin barrier function | Affects 3-5% of general population; infantile form (cradle cap) in 10% of infants under 3 months, 70% by 3 months; adult form prevalence 1-3% but up to 80-90% in HIV/AIDS patients; male predominance 1.5:1; higher prevalence in neurological disorders (30-80% Parkinson's patients) | Bimodal distribution: infantile form 2 weeks to 12 months (peaks 2-3 months); adult form typically 30-60 years with chronic relapsing course; can persist throughout life; rare in children between ages 2-12 years; HIV-associated form at any age with immunosuppression | Erythematous patches with greasy yellow scales; dandruff (mild variant affecting 15-20% of population); pruritus mild to moderate; symmetric distribution on scalp, face (nasolabial folds, eyebrows, glabella), ears, central chest; blepharitis and external otitis common; flexural involvement in severe cases; flares with stress, winter months; may be asymptomatic cosmetic concern | Sebum-rich areas: scalp; face; chest; back; external ear canal | Clinical diagnosis based on characteristic distribution and morphology; dermoscopy shows yellow scales, erythema, follicular plugging; KOH preparation shows Malassezia spores and hyphae; skin biopsy shows parakeratosis, spongiosis (rarely needed); differentiation from psoriasis, eczema based on scale quality and distribution | Topical antifungals first-line: ketoconazole 2% shampoo/cream twice weekly, ciclopirox 1% shampoo twice weekly; zinc pyrithione 1-2% shampoo; selenium sulfide 2.5% shampoo; topical corticosteroids short-term (hydrocortisone 1%, desonide 0.05%); calcineurin inhibitors for facial involvement (pimecrolimus 1%); keratolytics (salicylic acid 3-6%); oral antifungals for severe cases (fluconazole 50-100mg daily, itraconazole 200mg daily 1 week/month); maintenance therapy required | Chronic relapsing course with good symptomatic control; not curable but manageable; 80-90% respond to antifungal therapy; maintenance treatment prevents recurrence; flares common with treatment discontinuation; quality of life impact moderate; excellent cosmetic outcomes with consistent management; no malignant potential | L21.9 |
| 19 | 18 | Stasis Dermatitis | Inflammatory & Eczematous Disorders | Chronic venous insufficiency (CVI) as primary cause; venous hypertension with pressure 40-90mmHg (normal <20mmHg); valve incompetence in deep, superficial, or perforator veins; red blood cell extravasation and hemosiderin deposition; inflammatory cascade from leukocyte trapping; fibrin cuff formation around capillaries; growth factors and cytokines accumulation; risk factors include obesity (BMI >30), advanced age, history of deep vein thrombosis (DVT), pregnancy, prolonged standing | Affects 15-20 million Americans with CVI; prevalence increases with age (1-2% at age 30, 20-25% by age 70); female to male ratio 3:1; accounts for 70% of leg ulcers; 6-7% of population over 50 years has venous insufficiency; significant healthcare burden with annual costs >$3 billion in US | Typically develops in adults over 50 years; can occur in younger adults with DVT history or congenital venous abnormalities; chronic progressive course over years to decades; acute exacerbations triggered by infection or trauma; family history in 50-70% cases | Bilateral lower leg erythema, edema, scaling; pruritus often intense; hemosiderin deposition causing brown pigmentation; varicose veins present in 80%; lipodermatosclerosis (woody induration, inverted champagne bottle appearance); atrophie blanche (white atrophic scars); venous ulceration in 15-20% of untreated cases; weeping and crusting; secondary contact dermatitis in 40-50%; symptoms worse with dependency, improved with elevation | Bilateral lower extremities (medial malleoli most affected); dermis and subcutaneous tissue; venous system | Clinical diagnosis with characteristic findings; duplex ultrasound to assess venous insufficiency (sensitivity 95%); ankle-brachial index (ABI) to exclude arterial disease (normal >0.9); venography rarely needed; patch testing if contact dermatitis suspected; skin biopsy shows dermal fibrosis, hemosiderin deposition, dilated vessels (not routine) | Compression therapy cornerstone (30-40mmHg gradient stockings); leg elevation above heart 30 min 3-4 times daily; topical corticosteroids for dermatitis (triamcinolone 0.1% twice daily); emollients to restore barrier; pentoxifylline 400mg TID improves microcirculation; wound care for ulcers; antibiotics for secondary infection; avoid contact allergen exposure; treat underlying venous disease (endovenous ablation, sclerotherapy); pentoxifylline 400mg three times daily; horse chestnut seed extract 300mg twice daily | Chronic progressive condition requiring lifelong management; 60-70% improvement with consistent compression therapy; venous ulcers heal in 50-70% within 6 months with proper care; recurrence rate 60-70% without compression maintenance; significant morbidity if untreated; quality of life impairment moderate to severe; prognosis depends on compliance with compression and treatment of underlying venous disease | I87.2 |
| 20 | ▸ Papulosquamous & Psoriasiform Disorders | |||||||||||
| 21 | 19 | Darier Disease (Keratosis Follicularis) | Papulosquamous & Psoriasiform Disorders | Autosomal dominant genodermatosis caused by mutations in ATP2A2 gene encoding SERCA2 pump (sarco/endoplasmic reticulum Ca2+-ATPase); impaired calcium signaling in keratinocytes; abnormal cell-to-cell adhesion (acantholysis); defective desmosome formation; abnormal keratinocyte differentiation; 90% inherited, 10% de novo mutations; variable expressivity and incomplete penetrance; worsened by heat, UV exposure, friction, infections; secondary bacterial or viral infections common | Rare disorder; prevalence 1 in 30,000-100,000; affects all ethnicities equally; no gender predilection; autosomal dominant inheritance with 95% penetrance; 10% represent new mutations; variable severity within families; worldwide distribution; underdiagnosed due to mild cases; carriers always eventually develop some manifestations | Onset typically adolescence or early adulthood (11-15 years, mean 13 years); rare before age 5; can present in childhood or later adulthood; chronic progressive course; lifelong condition; severity variable; early childhood onset associated with more severe disease; flares triggered by heat, humidity, UV, friction, menstruation, pregnancy | Greasy, brown-yellow, hyperkeratotic papules in seborrheic distribution (scalp, face, chest, back); characteristic nail changes in 90%: longitudinal red and white streaks, V-shaped notching of nail tips, subungual hyperkeratosis; palmoplantar pits and keratotic papules; mucosal involvement (cobblestone papules in mouth 50%); malodorous due to secondary infection; keratotic plaques in flexures; heat and UV exacerbations; pruritus variable; acral hemorrhagic macules and vesicles; scarring in severe cases | Seborrheic areas: chest; back; flexures; scalp; face; nails (90%); palms and soles; oral mucosa (50%) | Clinical diagnosis with family history and characteristic nail changes; skin biopsy diagnostic: suprabasal acantholysis with dyskeratosis, 'corps ronds' (round bodies) in granular layer, 'grains' in stratum corneum, characteristic histology; genetic testing for ATP2A2 mutations confirms diagnosis; nail clipping biopsy shows characteristic features; no routine laboratory tests; rule out Hailey-Hailey disease (benign familial pemphigus), Grover disease | No cure; symptom management and prevention; sun protection and avoidance (UV triggers flares); topical retinoids (tretinoin 0.05-0.1%, adapalene 0.3% nightly) reduce keratosis; systemic retinoids most effective (acitretin 10-25mg daily, isotretinoin 0.5-1mg/kg/day) - 80-90% improvement but not curative; topical corticosteroids for inflammation; oral antibiotics for secondary infection (tetracyclines); antiseptic washes (chlorhexidine); botulinum toxin for malodorous affected areas; dermabrasion, ablative laser for cosmetic improvement; genetic counseling; avoid heat, UV, friction | Chronic progressive lifelong condition; variable severity (mild in 50%, moderate to severe in 50%); significant quality of life impairment in moderate-severe cases; malodorous secondary infections impact social functioning; systemic retinoids provide 80-90% improvement but require continuous use; discontinuation leads to relapse within weeks to months; neuropsychiatric manifestations in 5-15% (depression, learning difficulties, epilepsy); increased susceptibility to HSV (eczema herpeticum); normal life expectancy; 50% autosomal dominant transmission to offspring | Q82.8 |
| 22 | 20 | Erythrodermic Psoriasis | Papulosquamous & Psoriasiform Disorders | Most severe form of psoriasis involving >90% body surface area; triggered by withdrawal of systemic corticosteroids (40% of cases), infections, medications, phototherapy burns, severe plaque psoriasis progression; massive inflammatory response with cytokine storm; impaired thermoregulation from cutaneous vasodilation; protein loss from desquamation (10-25g/day); high-output cardiac state; increased metabolic demands; may be first presentation or occur in established psoriasis; calcium homeostasis disruption | Rare form accounting for 1-2% of psoriasis cases; incidence 0.1-0.2 per 100,000 annually; affects adults with mean age 50-60 years; male to female ratio 2-3:1; mortality rate 10-20% in acute cases; accounts for 1-2% of dermatology hospital admissions; higher mortality in elderly and those with comorbidities | Typically adults over 40 years with established psoriasis; can be initial presentation in 20-30%; acute onset over days to weeks; median age 50 years; may develop at any age; triggered events often identifiable; chronic relapsing course after initial episode; rare in children | Generalized erythema involving >90% body surface area; diffuse scaling and desquamation (shedding large sheets); pruritus intense; skin tightness and pain; edema especially hands and feet; nail changes (onycholysis, pitting); palmoplantar keratoderma; systemic symptoms: fever (38-40°C), chills, malaise, lymphadenopathy (70-90%); tachycardia; hypothermia or hyperthermia; high-output cardiac failure possible; arthralgia in psoriatic arthritis patients; hair loss | Generalized skin involvement (>90% BSA); nails; hair; systemic effects (cardiovascular, thermoregulation, metabolic) | Clinical diagnosis based on extent of involvement and psoriasis history; skin biopsy shows psoriasiform features (acanthosis, parakeratosis, Munro microabscesses, elongated rete ridges); complete blood count (leukocytosis, anemia); comprehensive metabolic panel (hypoalbuminemia <3g/dL, electrolyte imbalances, hypocalcemia); elevated liver enzymes; elevated ESR and CRP; uric acid elevated; total protein decreased; monitor cardiac function; blood cultures if sepsis suspected | Hospitalization required (intensive care if hemodynamically unstable); aggressive emollient application; fluid and electrolyte replacement; temperature regulation; nutritional support with high-protein diet; systemic therapy: cyclosporine 3-5mg/kg/day for rapid control, methotrexate 15-25mg weekly, acitretin 25-50mg daily; biologics (infliximab 5mg/kg at 0,2,6 weeks, adalimumab 80mg then 40mg Q2weeks, ustekinumab); topical corticosteroids mid-potency; antihistamines; antibiotics for secondary infection; avoid triggers including corticosteroid withdrawal; phototherapy after acute phase | Serious condition with guarded prognosis; mortality 10-20% from sepsis, pneumonia, cardiac failure; most respond to treatment with improvement over 2-4 weeks; chronic relapsing course in 30-40%; requires long-term systemic therapy; biologics have improved outcomes significantly; quality of life severely impaired; favorable response in 60-70% with aggressive treatment; risk of recurrence 30-50%; better prognosis if trigger identified and avoided; careful management of underlying psoriasis reduces recurrence | L40.8 |
| 23 | 21 | Guttate Psoriasis | Papulosquamous & Psoriasiform Disorders | Acute onset triggered by streptococcal pharyngitis (60-80% of cases); bacterial superantigens activate T cells; group A beta-hemolytic Streptococcus most common; molecular mimicry between streptococcal M protein and keratin; other triggers include viral infections (upper respiratory infections), stress, medications; genetic predisposition with HLA-Cw6 association; may be initial presentation of psoriasis or occur in known psoriasis patients; 40% of guttate cases progress to chronic plaque psoriasis | Accounts for 2% of all psoriasis cases; affects <30 years of age predominantly (peak 16 years); children and young adults; less than 2% of psoriasis presentations in adults >40 years; slight female predominance; associated with streptococcal infection in 60-80%; second most common psoriasis type after plaque; geographic variation correlates with streptococcal infection rates | Acute onset in children and adolescents (peak age 16 years); 80% occur before age 30; typically 2-3 weeks after streptococcal pharyngitis; acute self-limited course in 50%, chronic relapsing in 30%, evolution to plaque psoriasis in 40%; can recur with subsequent strep infections; rare in adults unless childhood history | Acute eruption of small drop-like (guttate) papules 2-10mm diameter; generalized distribution on trunk and proximal extremities; fine scale; bright red color; hundreds of lesions possible; sudden onset over days to 2 weeks; mild pruritus; face and ears often involved; upper respiratory infection preceding rash; resolves spontaneously in 3-4 months in 50% of cases or transitions to chronic plaque psoriasis; less scaling than plaque psoriasis | Trunk; proximal extremities; face; ears; generalized distribution | Clinical diagnosis with preceding pharyngitis history; throat culture or rapid strep test (often negative by presentation time); anti-streptolysin O (ASO) titer elevated (>200 IU/mL) in 60%; anti-DNase B elevated; skin biopsy shows psoriasiform hyperplasia, parakeratosis, neutrophils in stratum corneum (if diagnosis uncertain); differentiate from pityriasis rosea, secondary syphilis, drug eruption; complete blood count normal | Treat streptococcal infection if present: penicillin V 250-500mg QID 10 days or azithromycin 500mg day 1, then 250mg days 2-5; phototherapy first-line: narrowband UVB 3 times weekly (excellent response 80-90%); topical corticosteroids (triamcinolone 0.1% twice daily) and vitamin D analogues (calcipotriene 0.005%); emollients; limited systemic therapy usually needed; oral antibiotics even if culture negative may help; consider tonsillectomy for recurrent cases (reduces recurrence 50-60%); calcineurin inhibitors for facial lesions | Generally favorable prognosis; 50% achieve spontaneous remission within 3-4 months; 30% have chronic relapsing course; 40% eventually develop chronic plaque psoriasis within 10 years; excellent response to phototherapy with clearance in 80-90%; recurrence possible with subsequent streptococcal infections; children have better prognosis than adults; tonsillectomy may prevent recurrences in select cases; overall good long-term outcomes | L40.4 |
| 24 | 22 | Inverse Psoriasis (Flexural) | Papulosquamous & Psoriasiform Disorders | Genetic and immunologic factors similar to plaque psoriasis but manifestation in intertriginous areas; friction, moisture, occlusion modify clinical presentation; Candida colonization common (50-70%) but unclear if causative or secondary; obesity increases risk due to more pronounced skin folds; koebnerization from friction; same cytokine dysregulation (IL-17, IL-23, TNF-α) as plaque psoriasis; mechanical stress and maceration prevent scale formation; bacterial colonization modifies presentation | Accounts for 3-7% of psoriasis cases; affects 2-6% of psoriasis patients; higher prevalence in obese individuals (relative risk 2-3); all ages affected but more common in adults; slight female predominance due to submammary involvement; often coexists with plaque psoriasis (40-50% have both); underdiagnosed due to atypical appearance and location | Can occur at any age; often coexists with plaque psoriasis; onset similar to plaque type (bimodal peaks 20-30 and 50-60 years); chronic course with exacerbations; obesity-related cases may improve with weight loss; may be isolated form or part of generalized psoriasis | Well-demarcated, smooth, shiny erythematous plaques in intertriginous areas; minimal to no scaling (moisture prevents scale formation); symmetric distribution; affected sites: axillae, inguinal folds, submammary, intergluteal, genital; pruritus and irritation common; maceration and fissuring; painful in severe cases; secondary bacterial or Candida infection common; may have satellite lesions; sharp margination; burning sensation | Intertriginous areas: axillae; groin; submammary folds; intergluteal cleft; genital area; umbilicus | Clinical diagnosis challenging due to lack of typical psoriasis features; skin biopsy shows psoriasiform hyperplasia, less parakeratosis than plaque psoriasis (helpful if diagnosis uncertain); KOH preparation to identify Candida superinfection; fungal culture; examination for plaque psoriasis elsewhere supports diagnosis; Wood's lamp to exclude erythrasma (coral-red fluorescence); bacterial culture if cellulitis suspected | Topical calcineurin inhibitors preferred (tacrolimus 0.1%, pimecrolimus 1% twice daily) - no atrophy risk; low to mid-potency corticosteroids short-term (hydrocortisone 2.5%, desonide 0.05%); topical antifungals if Candida present (nystatin, clotrimazole twice daily); vitamin D analogues (calcitriol 3mcg/g); keep areas dry; absorbent powders; moisture-wicking fabrics; weight reduction if obese; systemic therapy same as plaque psoriasis if extensive (biologics, methotrexate); avoid high-potency steroids due to atrophy risk in intertriginous sites | Chronic relapsing course similar to plaque psoriasis; challenging to treat due to location and moisture; good response to calcineurin inhibitors in 60-70%; weight loss improves outcomes; recurrence common without maintenance; quality of life significantly impaired due to location and symptoms; favorable response to biologics if systemic therapy indicated; requires long-term management; prognosis good with appropriate therapy and preventive measures | L40.83 |
| 25 | 23 | Keratosis Pilaris | Papulosquamous & Psoriasiform Disorders | Common genetic condition with autosomal dominant inheritance and variable penetrance; follicular hyperkeratosis with retention of keratin in hair follicle openings; impaired desquamation; perifollicular inflammation; mutations in FLG gene (filaggrin) in some cases - same gene as atopic dermatitis; occurs in 50-80% of atopic individuals; abnormal keratinization of follicular epithelium; exact molecular defect unclear; worsens with low humidity and winter | Very common; affects 50-80% of adolescents, 40% of adults; childhood onset typical; higher prevalence in atopic individuals (80%); female predominance; all ethnicities affected; estimated 40% of general population has some degree; may be higher in fair-skinned individuals; often improves with age; family history in majority | Childhood onset typical (age 2-5 years); worsens in adolescence; may improve with age (30-50% improvement by adulthood); persists throughout life in many; seasonal variation with winter worsening; gradual onset; chronic stable course; no acute flares typically | Small rough follicular papules 1-2mm giving 'chicken skin' or 'goose bump' texture; keratotic plugs in follicles; erythema surrounding follicles (keratosis pilaris rubra); affects extensor arms (95%), thighs (60%), cheeks in children (30-50%); asymptomatic or mildly rough texture; minimal pruritus; may have follicular atrophy in severe cases; worsens with dry skin; cosmetic concern primarily; variants include keratosis pilaris atrophicans (atrophy and scarring, affects face) | Extensor surfaces: upper arms (posterolateral); thighs (anterolateral); buttocks; cheeks in children | Clinical diagnosis based on characteristic appearance and distribution; dermoscopy shows keratotic follicular plugs, perifollicular erythema; skin biopsy shows follicular hyperkeratosis, plugging, perifollicular lymphocytic infiltrate (rarely needed); no laboratory tests required; family history supportive; associated with atopic dermatitis (50-80%), ichthyosis vulgaris (30-40%) | No cure; treatment for cosmetic improvement; emollients with keratolytics (urea 10-20%, lactic acid 12%, salicylic acid 6%) twice daily; topical retinoids (tretinoin 0.05%, adapalene 0.1% nightly) - may cause initial irritation; alpha-hydroxy acids (glycolic acid 10-15%); topical corticosteroids low-potency for inflammation (hydrocortisone 1%); gentle exfoliation; humidifiers; avoid hot water; laser therapy (pulsed dye laser, IPL) for erythema; chemical peels; treatment must be continuous for benefit; improvement 50-60% with consistent topical therapy | Benign condition with good prognosis; not curable but manageable; 30-50% improve with age by 30s; chronic condition requiring ongoing management; cosmetic concern without health implications; treatment improves appearance in 50-60%; discontinuation leads to recurrence; no complications; quality of life impact minimal to moderate depending on severity and visibility; favorable outcomes with consistent emollient and keratolytic use; no malignant potential | L85.8 |
- Full dataset access
- Excel format
- Instant download